Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.

J Hematol Oncol · 2022 · PMC9590218 · PMID 36274163

Europe PMC DOI

hedged sentence

0.2330

closest p · 4.7× alpha

0.2330

boldest claim

The sentences

did not reach statistical significancep = 0.233not close (p > 0.1)

Earlier exposure to DARA-DCEP showed trends toward better survival, but the difference did not reach statistical significance (DARA-DCEP as second line treatment vs third line or beyond, median PFS 6 months vs 5 months respectively, p = 0.233, data not shown).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.